- Home
- SNT vs PSTV Comparison
SNT vs PSTV Comparison
Compare SNT & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNT | PSTV |
|---|---|---|
| Founded | 1965 | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.2M | 80.4M |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | SNT | PSTV |
|---|---|---|
| Price | $4.35 | $0.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 69.3K | ★ 10.2M |
| Earning Date | 11-25-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 257.88 | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $37,837,000.00 | $5,258,000.00 |
| Revenue This Year | N/A | $1.73 |
| Revenue Next Year | N/A | $12.05 |
| P/E Ratio | $20.62 | ★ N/A |
| Revenue Growth | ★ 9.82 | N/A |
| 52 Week Low | $2.57 | $0.16 |
| 52 Week High | $5.34 | $2.31 |
Technical Indicators
Market Signals| Indicator | SNT | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 54.42 | 26.25 |
| Support Level | $4.25 | $0.25 |
| Resistance Level | $4.52 | $0.61 |
| Average True Range (ATR) | 0.26 | 0.04 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 32.97 | 10.67 |
Price Performance
Historical ComparisonAbout SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).